FOXO1 and pulmonary arterial hypertension: As previously reported, FoxO1 is decreased in multiple cellular compartments in PAH (including the lungs and vascular smooth muscle cells), and a therapeutic enhancement has been proposed to alleviate the cardiopulmonary compromise.